Heterozygous pathogenic mutations in BARD1 were identified in 12 probands, resulting in a mutation frequency rates of 0.45% among high-risk breast cancer patients and 0.29% among ovarian cancer patients, while none of the BARD1 carrier had double heterozygous mutations. This evidence concerns the gene BARD1 and ovarian carcinoma.